BerGenBio announces advancement of its strategic review
Bergen, Norway, March 17, 2025 - Reference is made to the stock exchange announcement on 25 February 2025 from BerGenBio ASA (OSE: BGBIO) (the
"Company"), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for serious diseases, in which the
Company amongst other things announced that it will explore strategic alternatives. The Company today announced that it has engaged Carnegie AS[i], an
entity within the DNB Bank ASA group, as its financial advisor to assist in the Company's review of strategic alternatives. The management and Board of
Directors of the Company have together with Carnegie initiated exploration of potential strategic alternatives that may include, but are not limited to, an
acquisition, merger, business combination, sale of assets, licensing, or other transactions. The Company does not intend to disclose further developments
unless and until it is determined that further disclosure is appropriate or legally required.

The Company also announces that it has already implemented significant cost -containment and cash conservation measures.

https://newsweb.oslobors.no/message/641370

Verdiene i BGBIO skal synliggjøres. Aksjen har falt fra over 20 kroner siste året og fra enda mye høyere nivåer siste årene. Mange sitter med veldig høye snitt i denne, som ikke ønsker å selge på disse nivåer. Kan fort se et kraftig løft fremover mot videre strategiske avklaringer. Blir ikke overrasket over om aksjen skal prøve seg opp mot 5 - 7 kroner om ikke lenge. Blir momentumet sterkt nok ser vi aksjen over 10 kroner igjen om ikke lenge.